Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mecripyrine hydrochloride
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mecripyrine hydrochloride is an investigational small molecule drug being co-developed by Yantai YenePharma Co., Ltd and Simcere Pharmaceutical Group Ltd. It acts as an acetylcholinesterase (AChE) and tau protein hyperphosphorylation inhibitor. The drug is currently in Phase 1 clinical trials for the treatment of Alzheimer's disease and is administered orally as a tablet.
02
Targets
AcetylcholinesteraseMAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on mecripyrine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mecripyrine hydrochloride.